U.S. Stock Futures Slip After J&J’s Vaccine Trial Hits Snag

U.S. stock futures ticked lower Tuesday after Johnson & Johnson paused its coronavirus vaccine trials, prompting fresh speculation about when immunization shots may become widely available.

Futures tied to the S&P 500 fell 0.4%, suggesting that the gauge may lose some ground after the market opens. A rally in megacap tech stocks led the broad market index on Monday to its second-highest close in history.

J&J’s vaccine is one of the most advanced Covid-19 shots in development, and is among just a handful that had entered the last stage of testing in the U.S. This is the second time such a trial has been put on hold over a safety concern: AstraZeneca AZN 1.01% has since resumed its testing efforts in the U.K., but its clinical trials in the U.S. remain suspended.

“It’s a reminder that while we have this race to get a vaccine, it could actually take longer,” said Paul Jackson, global head of asset-allocation research at Invesco. People are also being too optimistic over how quickly a vaccine can halt the pandemic, he cautioned. “If we get one through the trials and authorized, that would be a great step, but then it will still take quite some time to get it widely distributed.”

J&J slid almost 3% ahead of the New York opening bell. The company is scheduled to report earnings at about 6:45 a.m. ET.

In bond markets, the yield on benchmark 10-year Treasury notes edged down to 0.757%, from 0.775% on Friday. The WSJ Dollar Index, which tracks the greenback against a basket of currencies, rose 0.2%.

Uncertainty about a second wave of infections and the extent to which governments may have to renew restrictions to control the spread is weighing on investors’ minds as the third-quarter earnings season kicks off on Tuesday.

“Earnings season will create a lot of volatility, especially ahead of the election,” said Ludovic Subran, chief economist at Allianz. “The market focus will remain on financial and tech earnings: this will be a main driver.”

A slew of financial companies including BlackRock, JPMorgan JPM 1.23% Chase and Citigroup will report results before the market opens, starting at about 6 a.m. ET. Their earnings will be closely scrutinized for fresh projections on loan defaults and indications on the health of the financial system.

“We will start to see that banks are in a very difficult position because of the low or negative interest rates in the U.S. and Europe,” Mr. Subran said. “The risk is more of a downside correction to financials.”

Delta Air Lines is also scheduled to report earnings on Tuesday morning.

Traders are also awaiting the latest inflation data, due out at 8:30 a.m. Consumer prices are expected to have risen in September for a fourth consecutive month. But inflation pressure is still likely to be muted, keeping the door open for the Federal Reserve to continue with its easy-money policy.

In trading ahead of the opening bell, Walt Disney rose 4.3% after it announced a major reorganization of its business to focus more on streaming.

Overseas, the pan-continental Stoxx Europe 600 fell 0.2%.

In Asia, most major benchmarks were mixed by the close of trading. The Shanghai Composite Index was flat after trade data showed that Chinese exports rose nearly 10% in September, reflecting a continuing recovery. Markets in Hong Kong were closed due to Tropical Storm Nangka being slated to hit the city.

The International Monetary Fund is also set to put out an updated outlook for global economic growth at 8:30 a.m., as finance ministers and central bankers gather virtually for the IMF and World Bank’s annual meetings.

Write to Anna Hirtenstein at [email protected]

The post U.S. Stock Futures Slip After J&J’s Vaccine Trial Hits Snag appeared first on WSJ.


Please enter your comment!
Please enter your name here